Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engert

Showing results (121-130 of 173) with videos related to

Pageof 18
Sort By:
The Cochrane Database of Systematic Reviews|October 19, 2007
Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphomaH Schulz, J Bohlius, N Skoetz, et al.
Annals of Hematology|August 12, 2003
Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trialJ-P Glossmann, A Engert, G Wassmer, et al.
Annals of Hematology|December 3, 2003
Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin BA Rothe, M Seibold, Th Hoppe, et al.
British Journal of Cancer|June 22, 1999
An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell lineA Klimka, S Barth, B Matthey, et al.
International Journal of Cancer|December 2, 1992
Growth of Hodgkin cell lines in severely combined immunodeficient miceC von Kalle, J Wolf, A Becker, et al.
Bone Marrow Transplantation|July 22, 1999
Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilizationM Reiser, A Josting, A Draube, et al.
Journal of Biological Response Modifiers|October 1, 1988
Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2J E Kolitz, G Y Wong, K Welte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 4, 2001
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphomaP Borchmann, R Schnell, R Knippertz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2013
Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitionsB Klimm, H Goergen, M Fuchs, et al.
Cancer Research|December 1, 1994
Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse modelC Gottstein, G Schön, S Tawadros, et al.
Pageof 18

Showing results (121-130 of 173) with videos related to

Sort By:
Pageof 18
The Cochrane Database of Systematic Reviews|October 19, 2007
Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphomaH Schulz, J Bohlius, N Skoetz, et al.
Annals of Hematology|August 12, 2003
Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trialJ-P Glossmann, A Engert, G Wassmer, et al.
Annals of Hematology|December 3, 2003
Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin BA Rothe, M Seibold, Th Hoppe, et al.
British Journal of Cancer|June 22, 1999
An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell lineA Klimka, S Barth, B Matthey, et al.
International Journal of Cancer|December 2, 1992
Growth of Hodgkin cell lines in severely combined immunodeficient miceC von Kalle, J Wolf, A Becker, et al.
Bone Marrow Transplantation|July 22, 1999
Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilizationM Reiser, A Josting, A Draube, et al.
Journal of Biological Response Modifiers|October 1, 1988
Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2J E Kolitz, G Y Wong, K Welte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 4, 2001
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphomaP Borchmann, R Schnell, R Knippertz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2013
Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitionsB Klimm, H Goergen, M Fuchs, et al.
Cancer Research|December 1, 1994
Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse modelC Gottstein, G Schön, S Tawadros, et al.
Pageof 18